Biotheus Inc.

Quick facts

Phase 3 pipeline

• PM8002 · Diabetes
  PM8002 is a small molecule that targets the SGLT2 receptor.

Phase 1 pipeline

• CD73 Antigen
• PM1021, PM8001
• PM1022

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Biotheus Inc. portfolio CI brief
• Biotheus Inc. pipeline updates RSS